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Abstract: Alternative splicing promotes proteome diversity by using limited number of genes, a key
control point of gene expression. Splicing is carried out by large macromolecular machineries, called
spliceosome, composed of small RNAs and proteins. Alternative splicing is regulated by splicing
regulatory cis-elements in RNA and trans-acting splicing factors that are often tightly regulated
in a tissue-specific and developmental stage-specific manner. The biogenesis of ribonucleoprotein
(RNP) complexes is strictly regulated to ensure that correct complements of RNA and proteins are
coordinated in the right cell at the right time to support physiological functions. Any perturbations
that impair formation of functional spliceosomes by disrupting the cis-elements, or by compromising
RNA-binding or function of trans-factors can be deleterious to cells and result in pathological
consequences. The recent discovery of oncogenic mutations in splicing factors, and growing evidence
of the perturbed splicing in multiple types of cancer, underscores RNA processing defects as a critical
driver of oncogenesis. These findings have resulted in a growing interest in targeting RNA splicing as
a therapeutic approach for cancer treatment. This review summarizes our current understanding of
splicing alterations in cancer, recent therapeutic efforts targeting splicing defects in cancer, and future
potentials to develop novel cancer therapies.
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1. Introduction
Humans and other higher metazoans have evolved by acquiring regulated diversity in their genes
by inserting multiple noncoding introns into a coding region. Alternative splicing promotes proteome
diversity without increasing the number of genes. With the advent of high-throughput sequencing,
it is now evident that about 95% of human multi-exon genes undergo alternative splicing [1,2].
To support physiological and cellular functions, alternative splicing is controlled with high fidelity in
tissue-specific, developmental stage-specific, and often gender-specific manners. It is further modulated
in response to intracellular signals or external stimuli. Humans exploit the most complex alternative
splicing regulation. The increasing complexity increases the possibility of splicing misregulation,
which potentially affects physiological functions and gives rise to various human diseases, including
cancers. The progress in high-throughput sequencing, and its application in sequencing human
tumors versus matched normal tissues, have provided the opportunity to identify tumor-specific
alternative splicing events. Splicing dysregulation can affect genes involved in virtually every step of
the transformation process [3]. However, in the past several years, we have observed that many of these
tumor-associated splicing changes arise due to alterations in particular components of the splicing
machinery [4,5]. Therapeutic approaches to modulate splicing events in several genetic diseases are
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reaching the clinic. However, splicing modulation in cancer is still in progress. In this review, we discuss
our current understanding of splicing alterations in cancer with mechanistic insights, highlight recent
and ongoing strategies to target splicing defects in cancer, and examine future opportunities to develop
novel cancer therapies.
2. Splicing Machinery, Splicing Code, and Splicing Catalysis
RNA splicing is a nuclear process catalyzed by large macromolecular machineries, known as the
major (recognizes ~99.5% of introns) and minor spliceosome (recognizes ~0.5% of introns), composed
of small RNAs and proteins [6]. Five small nuclear ribonucleoproteins (snRNPs) and multiple proteins
(>100) cooperate to form the spliceosome. Each snRNP is composed of a single uridine-rich small
nuclear RNA (snRNA) and multiple proteins. Splicing is accomplished in two steps: recognition of
intron/exon boundary and catalysis of the transesterification reaction to excise out an intron followed
by joining two exons. Recognition of intron/exon boundary is directed by essential splicing cis-elements
present within the intron, termed as consensus splice site sequences. These include 5′ splice site,
a branch point (BP), a polypyrimidine tract (PPT), and 3′ splice site. These splice sites are recognized
by essential splicing factors. In humans and metazoans, these consensus splice site sequences are
highly degenerative. Therefore, multiple auxiliary splicing factors cooperate to form functional
spliceosome to promote splicing. The assembly of spliceosome is further coordinated by auxiliary
splicing cis-elements: intronic/exonic splicing enhancers (ISEs/ESEs) and intronic/exonic splicing
silencers (ISSs/ESSs) (Figure 1A). The majority of splicing trans-factors for ESEs are serine/arginine
(SR)-rich proteins [7,8]. In contrast, the majority of splicing trans-factors for splicing silencer elements
(ISSs/ESSs) are heterogeneous nuclear ribonucleoproteins (hnRNPs) [9]. SR proteins contain one
or two RNA-recognition motif (RRM) at the N-terminal end and arginine and serine residues
(arginine/serine-rich (RS) domains) at the C-terminal end. In contrast, hnRNPs usually contain an
RRM-type and K homology (KH)-type RNA-binding domain along with other auxiliary domains.
Spliceosome assembly initiates with the recognition of the 5′ splice site by U1 snRNP, the BP by
SF1, and the PPT as well as 3′ terminal AG by U2AF heterodimer (U2AF65 and U2AF35, respectively).
This is an ATP-independent step, known as an E complex. An ATP-dependent spliceosome A complex
is then formed, where SF1 is replaced by U2 snRNP at BP. Subsequent recruitment of U4/U6-U5 snRNPs
leads to the formation of B complex. An active spliceosome complex called C complex is then formed by
replacing U1 and U4 snRNPs, which subsequently catalyzes splicing. Generally, splicing activators or
repressors modulate the early spliceosome assembly at the stage of E complex or A complex. Therefore,
the ultimate splicing consequence is accomplished by complex cis-acting splicing code, their cognate
RNA-binding trans-factors, and an enormous network of coordinated interactions.
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Figure 1. Splicing alterations in cancer. (A) Schematic of splicing regulatory cis-elements, which can 
influence alternative splicing regulation. Based on location and functional activity, these elements can 
be categorized into intronic/exonic splicing enhancers (ISEs/ESEs) and intronic/exonic splicing 
silencers (ISSs/ESSs). Exon inclusion or skipping is regulated by binding of cognate splicing trans-
factors, such as serine/arginine (SR) proteins and heterogeneous nuclear ribonucleoproteins 
(hnRNPs). (B) Mechanistic consequences of cancer-associated recurrent mutations in spliceosomal 
genes SRSF2, SF3B1, and U2AF1. Mutations in Pro95 of SRSF2 changes its RNA-binding specificity 
from a G-rich motif (GGWG, W = A/U) to a C-rich motif ((C/G)CWG). Mutations in SF3B1 alter 3′ 
splice site by enhancing recognition of cryptic upstream 3′ splice sites. Mutations in U2AF1 alter 3′ 
splice site consensus sequences. Wild-type U2AF1 recognizes the consensus motif yAG|r at the 
intron–exon boundary (y = pyrimidine, r = purine, ‘|’ = intron–exon boundary). S34F or S34Y 
Figure 1. Splicing alterations in cancer. (A) Schematic of splicing regulatory cis-elements, which can
influence alternative splicing regulation. Based on location and functional activity, these elements
can be categorized into intronic/exonic splicing enhancers (ISEs/ESEs) and intronic/exonic splicing
silencers (ISSs/ESSs). Exon inclusion or skipping is regulated by binding of cognate splicing
trans-factors, such as serine/arginine (SR) proteins and heterogeneous nuclear ribonucleoproteins
(hnRNPs). (B) Mechanistic consequences of cancer-associated recurrent mutations in spliceosomal
genes SRSF2, F3B1, and U2AF1. Mutations in Pr SF2 changes its RNA-bi ding specificity
from a G-rich motif (GGWG, = A/U) to a C-rich motif ((C/G)CWG). Mutations in SF3B1 alter 3′ splice
site by enhancing recognition f cryptic upstream 3′ splice ites. Mutations i U2AF1 alter 3′ splice
site consensus sequences. Wild-type U2AF1 recognizes the consensus motif yAG|r at the intron–exon
boundary (y = pyrimidine, r = purine, ‘|’ = intron–exon boundary). S34F or S34Y mutations promote
recognition of cAG|r over tAG|r, whereas Q157P or Q157R mutations promote recognition of yAG|g
over yAG|a. (C) Cancer-associated mutations in U1 small nuclear RNA (snRNA) and U11 snRNA.
(D) Mechanistic consequences for abnormal expression of splicing-factor in cancer. MYC increases the
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expression of splicing factors SRSF1, hnRNPA1, hnRNPA2, PTB, and hnRNPH, which subsequently
change the alternative splicing of downstream targets. SRSF1 promotes tumor specific splicing of BIN1
and CASC4. HnRNPA1, A2, and PTB promote the expression of PKM2, a cancer-specific variant of
PKM that induces aerobic glycolysis. HnRNPH promotes the expression of active oncogenic RAF
(ARAF full) while repressing the short RAF isoform (ARAF short).
3. Splicing Alterations in Cancer
Systematic and extensive sequencing of cancer versus normal tissues suggests that cancer cells
display ‘noisier’ splicing compared to normal tissue [10]. It is now well established that changes in
splicing affect every step of the oncogenic transformation. For example, tumor-specific increased
expression of anti-apoptotic isoforms have been documented in BCL2L1, CASP2, and FAS; alternative
splicing linked with the acquisition of invasive properties has been reported in CD44, FGFR2, RAC1,
and MST1R; and angiogenesis-specific splice variants are reported in VFGFA [11]. Tumor-associated
alterations in splicing occur either due to mutations in splicing regulatory cis-elements in RNA
or changes in components of the splicing machinery. These alterations are further regulated in a
tissue-specific or developmental stage-specific manner, and often also controlled by cellular signals or
external stimuli.
3.1. Mutations in Splicing Regulatory Cis-Elements in RNA
Recent analyses of whole-exome, whole-genome, and RNA-sequencing of tumor and normal
tissues from the same patients have provided important insights into the effects of somatic mutations
in splicing alterations in cancer [12,13]. One critical event reported is intron retention, which happens
more commonly than cassette exon splicing or alternative splice site selection and occurs in an
allele-specific manner. Moreover, mutation-induced intron retention was exclusively enriched in
tumor suppressor genes compared with oncogenes. Interestingly, most of the intron-retention events
resulted in the generation of premature termination codons (PTCs) compared with cassette exon
splicing events. The most commonly affected tumor suppressor genes included TP53 (encodes p53),
ARID1A (encodes a chromatin-remodeling factor), and PTEN (encodes a phosphatase regulating
phosphatidylinositol 3-kinase (PI3K) signaling) [13]. This is also evident in several clinically important
mutations that activate proto-oncogenes by altering critical splicing events. For instance, mutations
in the proto-oncogene MET (encodes a receptor tyrosine kinase) promoted skipping of exon 14 in
lung cancer [14–16]. In contrast, mutations in NOTCH1 (which encodes a trans-membrane receptor)
reported to activate a cryptic splice site and resulted in an aberrant isoform of NOTCH1 in chronic
lymphocytic leukemia (CLL) [17]. In addition to intronic mutations affecting splice sites, a substantial
proportion of somatic synonymous mutations have been reported within exons that affect ESE or
ESS sequences [12]. Surprisingly, synonymous exonic mutations were enriched within oncogenes
compared with tumor suppressor genes [12]. Furthermore, these synonymous mutations preferentially
resulted in a gain of ESE motifs and a loss of ESS motifs, which is not usually observed for synonymous
mutations in tumor suppressor genes [12].
3.2. Mutations in Components of the Splicing Machinery
In addition to mutations in splicing cis-elements as described above, numerous studies reported
recurrent cancer-associated mutations in genes of splicing machinery components, consisting of splicing
factors and small RNAs.
3.2.1. Mutations in Splicing Factors
Change-of-Function Mutations
Genomic sequencing of the myeloid malignancies unexpectedly discovered recurrent heterozygous
somatic mutations in several splicing factors [18]. Among these factors, SF3B1, SRSF2, and U2AF1,
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are most frequently mutated in patients with myelodysplastic syndrome (MDS), and also commonly
occurred in clonal hematopoiesis, acute myeloid leukemia (AML), CLL, and a variety of solid tumors
(Table 1) [18–20]. These mutations occur in highly restricted residues (hot spots) and are mutually
exclusive (Table 1). Although initially it was predicted that these mutations might affect common
downstream splicing targets, it is now evident that different mutations regulate hundreds of different
splicing targets [4,5,21,22].
Table 1. Alterations in splicing factor in cancer.
Gene Alteration Tumor Type Reference
SRSF2
Mutation MDS, AML, CMML, RARS, RCMD-RS,
MPN, UVM [4,11,18,19]Hot spot: P95
Overexpression Ovary
SF3B1
Mutation
MDS, AML, CMML, CLL, RARS, RCMD-RS,
MPN, UVM, MM, Breast, PDAC
[4,11,18,19]Hotspot: K700, E622, R625,
H662, K666
U2AF1
Mutation MDS, AML, CMML, RARS, RCMD-RS,
MPN, Lung [4,11,18,19]Hot spot: S34, Q157
ZRSR2
Mutation MDS, AML, CMML, RARS, RCMD-RS, MPN [4,11,18,19]
No hot spot
SRSF1 Amplification, overexpression Breast, lung, colon, ovary, thyroid kidney,small intestine [11,23,24]
SRSF3
Downregulation Liver
[11,25–27]Amplification, overexpression Ovary, cervix, breast, skin, stomach, bladder,thyroid, kidney, colon, liver
SRSF5 Overexpression Breast [28]
SRSF6 Amplification, overexpression Breast, Lung, colon, skin [23,29,30]
SRSF10 Overexpression Colorectal [31]
TRA2B Overexpression Breast, colon, glioblastoma, ovary [11,24,32,33]
RBM5
Downregulation Lung, prostate [34–36]
Overexpression Breast
RBM10
Mutation Lung [34,37]
Overexpression Breast
ESRP1,
ESRP2 Overexpression/downregulation Breast, oral [38,39]
HNRNPA1 Overexpression Glioblastoma, breast, colon, lung [23,40–42]
HNRNPA2/B1 Amplification, overexpression Glioblastoma [40]
HNRNPM Overexpression Breast [43]
HNRNPK
Downregulation AML
[44,45]Overexpression Breast, pancreatic, skin, esophageal,colorectal, oral
HNRNPH Overexpression Glioblastoma [46]
PTB Overexpression Breast, ovary, oral [27,47,48]
QKI Downregulation Lung adenocarcinoma, prostate, oral [49,50]
Note: MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia;
RARS, refractory anemia with ringed sideroblasts; RCMD-RS, refractory cytopenia with multilineage dysplasia
with ringed sideroblasts; MPN, myeloproliferative neoplasms; UVM, uveal melanoma; CLL, chronic lymphocytic
leukemia; MM, mucosal melanoma; PDAC, pancreatic ductal adenocarcinoma.
The splicing factor SRSF2 is a member of the SR-rich protein family. Cancer-associated recurrent
mutations in SRSF2 predominantly occur at the Pro95 codon, which is in close proximity to the RRM
domain [18]. These mutations in SRSF2 mutations show worse survival outcomes in MDS and an
increased risk of transformation to AML [51]. Mutations in Pro95 of SRSF2 changes its RNA-binding
specificity from a G-rich motif (GGWG, W = A/U) to a C-rich motif ((C/G)CWG) (Figure 1B) [52–55].
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These gain-of-function mutations trigger genome-wide splicing alterations, affecting functions of
many proteins, including important regulators associated with hematopoiesis. In addition to altered
splicing, several mRNA isoforms promoted by mutant SRSF2 contain a PTC and are degraded by
nonsense-mediated mRNA decay (NMD). Recently, it has been shown that mutations in SRSF2 also
enhance its NMD-stimulating activity which is also promoted by sequence-specific RNA-binding
and subsequent enhancement of exon junction complexes (EJCs) downstream from the PTC [55].
One notable example is EZH2, encoding enhancer of zeste homolog 2 protein, which catalyzes histone
methylation and functions in chromatin remodeling. Pro95 mutation in SRSF2 promotes the inclusion
of a poison exon in intron 8 of EZH2, resulting in a transcript with a PTC, which is degraded by NMD.
Other important target genes include INTS3 (a member of the integrator complex), ARMC10 (tumor
suppressing factor), FYN (the tyrosine kinase), BCOR (also recurrently mutated in AML and MDS),
IKAROS (associated with the renewal of stem cell), and CASP8 (a regulator of apoptosis) [52–55].
The splicing factor SF3B1 is a subunit of U2 snRNP, which promotes the stabilization of the U2
snRNP at the branch point during spliceosome assembly. Recurrent mutations in SF3B1 typically
occur in the highly conserved C-terminal domain, between the fourth and eighth HEAT domain
repeats [18,19]. About half of these missense mutations affect amino acid residue K700, whereas other
mutations affect nearby hotspots (R625, H662, and K666) (Table 1). According to several studies,
these mutations promote the activation of cryptic 3′ splice site (Figure 1B) [20,56–62]. These result in
many mRNAs with a PTC, which are subsequently degraded by NMD. However, there is no evidence
of a direct role of SF3B1 mutations in the NMD pathway to date. One notable altered spliced target
in SF3B1 mutant cells is ABCB7, encoding the mitochondrial iron exporter protein. Aberrant usage
of 3′ splice site in ABCB7 causes retention of a 21-bp intronic segment, which generates a PTC and
is subsequently degraded by NMD [58]. Some other dysregulated genes include ALAS2, SLC25A37,
ASXL1, CBL, CRNDE, TMEM14C, UQCC1, etc. [20,56–62].
The splicing factor U2AF1 is a subunit of the U2 snRNP, which promotes recognition of the AG
dinucleotide at the 3′ splice site (SS). Recurrent mutations in U2AF1 mostly affect residues at S34 or
Q157, respectively, spanning two separate and conserved zinc finger domains (Table 1) [18,19]. U2AF1
mutations show worse survival and an increased risk of transformation to AML [51,63]. Mutations in
S34 and Q157 differentially affect the recognition of 3′ splice site. S34 mutants promote recognition
of 3′ SS bearing a C or A immediately preceding the AG (Figure 1B) [64–68]. In contrast, Q157
mutants promote recognition of 3′ SS harboring a G immediately downstream of AG (Figure 1B) [66].
Two notable targets in U2AF1 S34 mutant cells are H2AFY (encoding an H2A histone variant) and
STRAP (encoding serine/threonine kinase receptor-associated protein) [68]. Some other reported target
genes in U2AF1 mutant cells include PICALM, MED24, GNAS, BCOR, KDM6A, etc. [64–72].
As splicing factor mutations occur in a mutually exclusive manner, initially it was anticipated that
these mutations might affect common downstream splicing targets. However, it is now established
that each of the mutations affect different splicing targets. These disparate effects directed a search for
convergent effects of these mutations in processes unrelated to splicing. To this end, it was revealed
that mutations in U2AF1 [73] and SRSF2 [74] promote the formation of R-loops, which are defined as
three-stranded structures composed of DNA–RNA hybrids. The increased R-loops in cells bearing
mutations in SRSF2 or U2AF1 subsequently cause increased DNA damage and activation of the
ATR (ataxia telangiectasia and Rad3-related protein) pathway. These data represent a novel effect
of mutant U2AF1 and SRSF2 with important therapeutic implications. Going forward, it will be
important to investigate whether mutant SF3B1 similarly impacts R-loop generation. Apart from
R-loops, a recent report proposed that the U2AF1 S34F mutation affects interactions with the cleavage
and polyadenylation (CP) machinery [75], which causes increased usage of a distal CP site and longer
3′ untranslated regions (UTRs). For example, altered CP of the mRNA encoding the autophagy ATG7
caused downregulation of ATG7, perturbed autophagy, and accumulation of secondary mutations.
It will be important to determine whether other mutations in U2AF1 or SRSF2 or SF3B1also alter CP
usage, 3′ UTR length, or autophagy.
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In addition to the core spliceosome components described above, alterations in other RNA-binding
proteins have also been reported in cancer, including hematological malignancies (such as MDS, de novo
AML, or CLL). These mutations were reported in PRPF8, SF3A1, LUCL7L2, SF1, U2AF2, HNRNPK,
SRSF6, SRSF1, SRSF7, TRA2β, SRRM2, DDX1, DDX23, CELF4, HN, RBM10, SFPQ, PHF5A, HNRNPCL1,
PCBP1, PCBP2, FUBP1, FUBP3, QKI, etc. [76–79]. The existence of such mutations suggests that
alterations in multiple steps of spliceosome assembly and splicing regulation can contribute to cancer
development and pathogenesis.
Loss-of-Function Mutations
In contrast to recurrent change-of-function mutations in SRSF2, SF3B1, and U2AF1, in highly
restricted residues or hot spots, ZRSR2 mutations in MDS are distributed throughout the gene [18].
These mutations span the X chromosome (Xp22.1) and frequently interrupt the coding sequence by
directly or indirectly introducing in-frame stop codons. These mutations appear to be loss-of-function
mutations, and mostly affect splicing of U12-type introns [80]. Examples of altered splicing events
promoted by mutations in ZRSR2 include expression of MAPK (mitogen-activated protein kinases)
pathway members and E2F transcription factors. Loss-of-function mutations have also been reported
in the splicing factor RBM10. These mutations are associated with lung, bladder, and thyroid
carcinomas [37,79,81]. RBM10 mutations identified in lung cancer cells disrupt splicing of NUMB,
an inhibitor of NOTCH signaling, and promote cell growth [82]. Loss-of-function mutations reported
in other splicing factors include FUBP1, FUBP3, PCBP2, QKI, etc. [79].
3.2.2. Mutations in snRNA
Although recurrent somatic mutations in cancer are exclusively identified in protein-coding genes,
very recently recurrent mutations in spliceosomal snRNAs have been reported in cancer patients,
mostly in U1 snRNA, and a small percentage in U11 snRNA (Figure 1C) [83,84]. U1 snRNA functions
in recognition of 5′ splice site. Two prominent mutations at base-position 3 in U1 snRNA were
identified (3A > C and 3A > G), which span within the 5′ splice site binding region (Figure 1C) [83,84].
The 3A > C mutation was identified in medulloblastoma (MB), CLL, hepatocellular carcinoma (HCC),
B-cell non-Hodgkin lymphoma (B-NHL), and pancreatic adenocarcinoma (PC). In contrast, the 3A > G
mutation was reported exclusively to MB (most prominently in the Sonic hedgehog MB subtype).
snRNA-mutant tumors display significant aberrant splicing, with an excess of cryptic 5′ splice site
events [83,84]. Mutant U1-snRNA-promoted alternative splicing inactivates tumor suppressor genes
(such as PTCH1) and activates oncogenes (such as GLI2 and CCND2). Mutation in U11 snRNA was
reported at base position 5 (5A > G), which also spans in the highly conserved region of 5′ splice
site [83]. Mutations in snRNA exemplify a novel target for therapy and represent highly recurrent and
tissue-specific mutations of non-protein coding genes in cancer.
3.2.3. Abnormal Expression of Splicing Factors
Although recurrent mutations in splicing regulators have been frequently identified in hematologic
malignancies, few such mutations have been detected in solid tumors [11]. This suggests a
difference in splicing targets and/or splicing regulation in hematological malignancies compared
to solid tumors. Interestingly, solid tumors display alterations in splicing factors, such as changes
in levels, changes in gene copy number and/or changes in gene expression (Table 1). Some of
these splicing factors exert oncogenic properties, whereas some show tumor suppressing activities.
For example, SRSF1 [23,85], SRSF3 [25], SRSF6 [23,29], hnRNPA2/B1 [40], or hnRNPH [46], often display
oncogenic properties. In contrast, RBM5, RBM6, RBM10 [82], or QKI [86], act as tumor suppressors.
These RNA-binding proteins often regulate alternative splicing in a concentration-dependent manner.
Therefore, relative changes in their expression level in the context of particular cancer types can alter
global splicing regulation. These alternative splicing changes subsequently regulate many of the
cellular processes known as “hallmarks” of cancer, such as cell proliferation, apoptosis, metabolism,
Cancers 2020, 12, 1381 8 of 26
invasion, and angiogenesis. However, the pathological consequences of these global splicing alterations
are only beginning to be discovered. Here we will briefly discuss several examples.
The expression of splicing factors is often regulated by oncogenic signaling [11,85,87].
The transcription factor MYC, commonly amplified in cancers, induces the expression of several
splicing factors, and subsequently contributes to altered splicing (Figure 1D). One of the earliest
examples of the MYC-regulated splicing target was the glycolytic enzyme, pyruvate kinase (PKM).
There are two mutually exclusive isoforms of PKM: PKM1 and PKM2. PKM1 is expressed in normal
adult tissues and promotes oxidative phosphorylation. In contrast, PKM2, which is upregulated
in many cancers, promotes aerobic glycolysis. MYC upregulates transcription of specific hnRNPs
(hnRNPA1, hnRNPA2, and PTB) (Figure 1D). These alterations subsequently promote the expression
of the PKM2 isoform and aerobic glycolysis in glioma (Figure 1D) [3,88].
Several SR proteins, such as SRSF1, SRSF3, and SRSF6, are also amplified in multiple cancer
types (Table 1) [25,29,30]. SRSF1 is also reported as a direct transcriptional target of MYC [85,89].
It was shown that upregulated expression of SRSF1 promotes transformation of human and mouse
mammary epithelial cells, which regulate splicing of hundreds of transcripts [23,85]. Some of the
SRSF1-regulated splicing events include the MST1R (Ron) proto-oncogene and the kinases MKNK2
and S6K1, which induce the expression of pro-oncogenic isoforms [23,85,90]. SRSF1 also regulates
splicing of the apoptotic factor BCL2L11 (BIM) generating the protein lacking pro-apoptotic activity [85].
In addition, SRSF1 regulates splicing of the tumor suppressor BIN1 [85]. In breast cancer, SRSF1
promotes the inclusion of exon-9 of CASC4 (Figure 1D). It has been reported that expression of the
exon-9-included CASC4 isoform increases proliferation and decreases apoptosis, partially recapitulating
SRSF1′s oncogenic effects [91]. In contrast to overexpression of SRSF1, downregulation of SRSF3 elicits
p53-mediated cellular senescence, which is regulated via expression of p53β, an alternatively spliced
isoform of p53 [92]. Another target of MYC is hnRNPH. Enhanced expression of hnRNPH regulates
splicing of active oncogenic RAF (ARAF) kinase [93], increasing the expression of the long isoform
(ARAF full) that promotes RAS-induced transformation (Figure 1D).
3.3. Post-Translational Modification of Splicing Factors
Post-translational modifications can alter the function of splicing factors or change the
nuclear-cytoplasmic distribution. These modifications include phosphorylation, methylation,
acetylation, sumoylation, etc. These modifications are regulated by signaling pathways.
For example, the localization and functional activities of SR proteins are regulated by
phosphorylation/dephosphorylation dynamics, mostly at serine residues within the RS domain.
Phosphorylation of SRSF1 enhances protein–protein interactions with other splicing factors harboring
the RS domain, such as U1–70K [94]. In contrast, dephosphorylation of SR or SR-related proteins
promotes splicing catalysis [95,96]. The major regulators of SR protein phosphorylation include SR
protein kinase family (SRPK), Clk/Sty kinase family and topoisomerase I [10,11,97]. Cancer-associated
splicing events are often regulated via SR protein phosphorylation. For example, phosphorylation of
SRSF1 and SRSF7 by AKT kinase promote growth-factor induced alternative splicing of the fibronectin
EDA exon [98]. This effect was predicted to be an indirect regulation via SRPKs. Subsequently it was
shown that SRPKs are indeed activated by AKT in response to EGF-signaling, which subsequently
enhanced SRPK nuclear translocation and SR protein phosphorylation [99]. Several components of the
AKT pathway have been reported to function as oncogenes or tumor suppressors. Overexpression of
SRPK1 is also evident in multiple tumor types [100–104]. In addition to SR proteins, hnRNPs and other
SR proteins are also regulated by post-translational modifications; for example, alternative splicing of a
four-exon cassette in the CASPASE-9 gene [105,106]. The exon included isoform (CASPASE-9a) functions
as a proapoptotic variant, whereas the exon excluded isoform (CASPASE-9b) acts as an antiapoptotic
variant. Mechanistic investigation revealed that AKT-dependent phosphorylation of hnRNP L promotes
exon skipping, and generates the antiapoptotic variant [105,106]. This subsequently promotes cell
survival. In contrast, AKT-mediated phosphorylation of hnRNP A1 affects the translational activity,
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rather than splicing regulation. Phosphorylated hnRNP A1 is unable to induce IRES dependent
translation of the CCND1 and c-MYC mRNAs [107].
4. Targeting Splicing Alterations for Cancer Therapies
As described above, it is now well established that cancer cells display widespread alterations
in RNA splicing compared to normal cells. These findings suggest that modulating of RNA splicing
factors by targeting specific transcripts, or even genome-wide, may have significant therapeutic
potential. Here we discuss different therapeutic avenues of splicing modulation for cancer therapies,
current progress, and future perspectives.
4.1. Targeting Core Spliceosome
In last two decades, multiple studies screened natural compounds for antitumor activity.
Taken together, these led to the identification of several bacterially derived products. These can be
categorized into three classes: pladienolides (such as pladienolides A–G); herboxidienes (such as GEX1A,
6-norherboxidiene), and spliceostatin (such as FR901463, FR901464, FR901465) (Table 2) [10,108,109].
Following the promising cytotoxic effects of these compounds in animal models, synthetic analogues
were produced with improved chemical properties, including solubility, stability, potency etc.
Among these analogues, noteworthy examples include E7107 (an analogue of pladienolide B),
spliceostatin A (FR901464 derivative), meayamycin, sudemycin, etc. (Table 2). Although these
compounds have different chemical structures, all of these drugs target the SF3B complex of the U2
snRNP (notably SF3B1 and PHF5A) and disrupt the early assembly of spliceosome (Figure 2A) [110–113].
This common effect drew promising attention for further investigation targeting the spliceosome for
cancer therapy. Following the promising and selective antitumor activity of E7107 in human xenograft
models, it was tested into two separate phase I clinical trials including 66 patients with locally advanced
or metastatic solid tumors [114,115] (clinicaltrials.gov identifier NCT00499499). Although the tumors
showed promising response in some patients, the visual side effects in a few patients precluded the
clinical development of E7107 further. Whether the observed toxicity is a target-specific effect of
SF3B1 inhibition, or an effect specifically associated with E7107, needs further elucidation. Further
investigation is required to determine the safety margin and therapeutic efficacy of other structurally
distinct forms of the pharmacologic compounds targeting the SF3B complex.
Table 2. Small molecule splicing modulators in cancer.
Compound Target ofInhibition Mechanism(s) of Action Reference
Pladienolide:
SF3B complex
Interact with SF3B1 and promote conformational alteration
[10,116–118]Pladienolides A–G
Antitumor activities reported in human BSY-1, PC-3,
OVCAR-3, DU-145, WiDr, HCT-116 cells, primary human
colon cancer cells, xenograft mouse model, etc.
Pladienolide
analog: SF3B complex
Interacts with SF3B1 and promotes splicing alteration
[10,118–120]
E7107 Inhibition of tumor growth in human breast, ovary,non-small cell lung cancer, xenograft mouse model, etc.
Spliceostatin:
SF3B complex
Interface interaction of U2 snRNP with pre-
[10,118,121,122]
FR901463
FR901464
mRNAFR901465
Meayamycin B Antitumor activities reported in murine solid tumors (colon
38 and Meth A), human lung adenocarcinoma solid tumor
(A549), human colorectal carcinoma (HCT-116), human
prostate tumor (PC-3), human rhabdomyosarcoma (rh18),
xenograft mouse model, etc.
Spliceostatin A
Sudemycins
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Table 2. Cont.
Compound Target ofInhibition Mechanism(s) of Action Reference
Sufonamides:
RBM39
Bind a receptor of the CRL4 E3 ubiquitin ligase complex
(known as DCAF15), and direct ubiquitin-mediated
degradation of RBM39
[123–125]Indisulam
Tasisulam
E7820
SRPK inhibitor:
SRPK1 and
SRPK2
Competitively inhibit SRPK1 and SRPK2, subsequently
affect SR protein phosphorylation
[126–128]
SRPIN340
SRPKIN-1
SRPIN340 is reported to block angiogenesis and related
tumor growth in nude mice
SRPKIN-1 is reported to convert the proangiogenic VEGF
isoform to the angiogenic isoform
CLK inhibitor:
CLK1, CLK2,
CLK4
Competitively inhibit CLK1, CLK2, and CLK4,
and subsequently affect SR protein phosphorylation
[10,129,130]
T-025
TG003 T-025 is reported to affect global alternative splicing,inducing cancer cell death, and inhibiting cancer cell growth
SRPK and CLK
SRPK1, SRPK2,
CLK1, CLK2
Inhibit SRPK1, SRPK2, CLK1, and CLK2, and subsequently
affect SR protein phosphorylation [10,118,131]
inhibitor:
Cpd-1
Cpd-2
Cpd-3
Topoisomerase I
inhibitor: Topoisomerase I
Inhibitory effect prior to step one of splicing
[132]
NB-506 Inhibits SRSF1 phosphorylation and splicing of Bcl-X, CD44,SRSF2, and Sty in P388 cultured cells
Amiloride Unknown Inhibits SRSF1 phosphorylation and splicing of Bcl-X,HIPK3, and RON/MISTR1 in Huh-7 cultured cells [133]
Note that SF3B complex is important for splicing, therefore general splicing inhibition has a
high chance to be catastrophic for cells. Interestingly these drugs exert specific cytotoxicity to cancer
cells [108]. The discovery of recurrent heterozygous mutations in components of spliceosome (such as
SRSF2, SF3B1, and U2AF1) [18,135] emphasized the need to test these drugs for preferential sensitivity
in spliceosomal-mutants. One notable fact is that cells with mutations in these genes retain expression
of the wild-type allele and never become hemizygous. This suggests haplo essentiality of mutations
in SRSF2, SF3B1, and U2AF1, and suggests that increased expression of the mutant allele is tightly
regulated. E7107 treated isogenic murine myeloid leukemias showed preferential cell death of leukemia
cells with mutated Srsf2 compared to wild-type Srsf2 [136]. A similar finding was observed for U2AF1
mutated cells treated with sudemycin [137]. However, there is no clinical evidence of the effects
of SF3B inhibition on spliceosomal-mutant cancer. However, a phase I clinical trial of an orally
administered SF3B inhibitior (H3B-8800) is currently ongoing in patients with AML, MDS, and chronic
myelomonocytic leukemia (clinicaltrials.gov identifier NCT02841540). This trial will provide critical
information about the safety margin of H3B-8800 in patients and efficiency of splicing modulation in
patients. Further investigation in isogenic cancer cells with or without recurrent mutations will be
necessary to understand the mechanistic insights of the pharmacological compounds whether they
affect pre-mRNA cis-elements and/or aberrant protein(s) responsible for the preferential lethality in
mutant cells.
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Figure 2. Therapeutic approaches of splicing modulation in cancer. (A) Pharmacological
splicing inhibition using drugs that physically bind to the SF3B complex and disrupt its ability
to recognize the branchpoint within the intron. See Table 2 for representative examples.
(B) Anticancer sulfonamide compounds promote degradation of RBM39. These compounds
physically connect RBM39 to the DCAF15-CUL4 ubiquitin ligase, resulting in ubiquitinylation
of RBM39. This subsequently promotes proteasomal degradation of RBM39. See Table 2
for representative examples. (C) Pharmacological inhibition of post-translational modifications
using drugs that interfere with the functions of several enzymes, including SR protein kinase
family (SRPK), CDC2-like kinases (CLKs), and AKT kinases. See Table 2 for representative
examples. (D) Decoy oligonucleotides containing short repeats of RNA-binding motifs can inhibit the
Cancers 2020, 12, 1381 12 of 26
function of specific splicing factor by sequestering them and prohibiting binding to the target transcript(s).
One representative example was the transfection of specific decoy oligonucleotides into cancer
cells targeting SRSF1-binding which resulted in changes in splicing of known targets of SRSF1,
including MKNK2 [134]. This subsequently activated the p38–MAPK stress pathway and inhibited
the proliferation and survival of cancer cells [134]. (E) Antisense oligonucleotides (ASOs) can bind to
splicing regulatory sequences or motifs in a targeted transcript, and switch splicing to a favorable isoform.
One representative example was specific ASOs targeting a poison exon of BRD9 in SF3B1-mutant cells,
which showed satisfactory results in splicing modulation and suppressing tumor growth [62].
4.2. Targeting Splicing Regulatory Proteins
4.2.1. Sulfonamides
Several sulfonamide-containing compounds (such as indisulam, tasisulam, E7820,
chloroquinoxaline) are known to show antitumor activity (Table 2). Several sulfonamides have
already completed phase I and II clinical trials. For example, indisulam has been used in
phase II clinical trials for patients with AML, melanoma, and non-small cell lung cancer with
a satisfactory safety margin but limited efficacy [138–140]. The underlying mechanisms of how
sulfonamide-containing compounds work were not known during the studies, which limited the
opportunity to follow up the pharmacodynamic properties and mode of actions of these compounds.
Two recent reports identified the U2AF-related splicing factor RBM39 as the target of several anticancer
sulfonamide-containing compounds [123,124]. They showed that several sulfonamides promote
ubiquitin-mediated degradation of RBM39 via CRL4 E3 ubiquitin ligase complex, known as DCAF15
(Figure 2B). It is important to note that RBM39 degradation was sensitive to a limited number of
cancer cells [123,124]. RBM39 degradation interferes with splicing [141]. Interestingly, leukemia
cells harboring splicing factor mutation showed similar sensitivity to RBM39 degradation similar to
inhibition of SF3B complex [141], highlighting the promising therapeutic potentials of sulfonamides
for spliceosomal-mutant cancer cells.
4.2.2. Decoy Oligonucleotides
An attractive approach for targeting splicing regulatory proteins is via decoy oligonucleotides.
These oligonucleotides are designed to contain short repeats of RNA-binding motifs targeting specific
RNA-binding splicing factors in order to inhibit their function (Figure 2D) [134]. In a recent study, decoy
oligonucleotides were developed targeting splicing factor SRSF1. As noted earlier, SRSF1 is frequently
overexpressed in several different tumors, including lung, colon, breast, etc. [23,85,142]. SRSF1
overexpression affects global splicing regulation, promoting the expression of several pro-oncogenic
isoforms, such as MST1R (Ron) proto-oncogene, and kinases like, MKNK2 and S6K1 [23,85,90].
Transfection of specific decoy oligonucleotides into cancer cells targeting SRSF1-binding resulted in
changes in splicing of known targets of SRSF1, including MKNK2 [134]. This subsequently activated the
p38–MAPK stress pathway and inhibited the proliferation and survival of cancer cells [134]. This shows
the promising potential of decoy oligonucleotide technology to treat cancers with upregulated or
hyperactive splicing factors. However, one challenge behind this technology is several splicing
factors with binding affinities for similar motifs might be sequestered; therefore, their downstream
splicing targets could be aberrantly regulated and result in compromised biological functions. Careful
considerations should be employed to test the feasibility and safety margin of this technology.
4.3. Targeting Post-Translational Modification
In addition to targeting spliceosome, efforts have been employed in developing drugs targeting
post-translational modifications, an important regulation associated with spliceosome function.
As noted earlier, post-translational modifications can alter the function of splicing factors or change
the nuclear-cytoplasmic distribution. These modifications include phosphorylation, methylation,
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acetylation, sumoylation, etc., and are regulated by signaling pathways. Compounds with inhibiting
properties of post-translational modifications have been reported to show promising anticancer effects
(Figure 2C). One notable example is inhibition of phosphorylation of SR family proteins: SR proteins
RRM at the N-terminal and an RS domain at the C-terminal [143,144]. The RS domains harbor
multiple consecutive RS–SR dipeptide repeats, which are extensively phosphorylated by multiple
kinases, including members of the SRPK family (SRPK1 and SRPK2), and the CDC2-like kinase (CLK)
family (CLK1 to CLK4) [145,146]. Phosphorylation of SR proteins is often critical for the formation
of spliceosome complex. In contrast, dephosphorylation promotes splicing catalysis to occur and
promotes nuclear export of SR proteins. Screening of a series of chemical compounds or effects on
in vitro phosphorylation of CLKs picked the benzothiazole compound TG-003 as a potential inhibitor
of CLK1, CLK2, and CLK4 (Table 2) [129]. Although the global effects of TG-003 are still not well
understood, the drug affects expression of the functional isoforms of CLK1 and SRSF2 [129]. Another
oral treatment with the CLK inhibitor T-025 showed promising effects in cancer cells affecting alternative
splicing, inducing cell death, and inhibiting cancer cell growth [130]. Screening for inhibitors of SRPK
kinase activity identified Cpd-1, Cpd-2, and Cpd-3 [147]. These compounds inhibit SPRK1, SRPK2,
and/or CLK1 and CLK2 [147]. Another example is SRPKIN-1, inhibitor of SRPK1 and SRPK2, which was
reported to reduce SR protein phosphorylation, and subsequently promote the proangiogenic splicing
isoform of VEGF (VEGF-A165a) to the anti-angiogenic VEGF- A165b isoform in a murine retinal
model [126].
Another important example of post-translational modifications is arginine methylation.
For example, the enzyme protein arginine N-methyltransferase 5 (PRMT5), which catalyzes symmetric
dimethylation of arginine, is important for snRNP assembly and normal splicing [148,149]. Chemical
inhibition of PRMT5 showed splicing inhibition and anticancer effects across a number of cancer
types [150,151]. At least three PRMT5 inhibitors are now in phase I clinical trials for patients
with relapsed/refractory solid tumors: GSK3326595 (clinicaltrials.gov NCT02783300); PF 06,939,999
(clinicaltrials.gov NCT03854227); JNJ-64619178 (clinicaltrials.gov NCT03573310). In contrast to PRMT5,
PRMT1 catalyzes asymmetric dimethylation of arginine. PRMT1 is overexpressed in multiple
cancers [152]. PRMT1 methylates splicing factor RBM15, triggering its ubiquitylation and subsequent
degradation [153]. RBM15 is reported to bind to specific intronic sequences of genes encoding proteins
with important roles in hematopoiesis [152]. Overexpression of PRMT1 reduces the expression of
RBM15, and subsequently affects megakaryocyte terminal differentiation [152]. A phase I clinical
trial with PRMT1 inhibitor is ongoing (GSK3368715) (clinicaltrials.gov NCT03666988). Combinatorial
treatment with the PRMT1 and PRMT5 inhibitors MS023 and EPZ015666 was tested in a preclinical
study, which showed efficient anticancer effects in small-cell lung cancer and pancreatic cancer cell
lines [154].
4.4. Targeting MYC-Oncogene
Targeting MYC-onogene has significant therapeutic potentials for preferential splicing modulation
in cancer. This is because MYC is the most frequently amplified oncogene in human cancers and plays a
critical role in transformation. In addition, an important correlation between the MYC and the splicing
machinery has been identified. Genes encoding several splicing regulatory proteins, such as SRSF1,
PTB, HNRNPA1, and HNRNPA2, were reported to be direct transcriptional targets of MYC [3,85,89,91].
SRSF1 not only assists MYC’s oncogenic activity [89], but also contributes to its effects in transformation,
promoting more aggressive forms of breast tumors by altering global splicing regulation [85,91]. On the
other hand, hnRNPA1 and hnRNPA2 regulate alternative splicing of the cancer-associated muscle
pyruvate kinase (PKM) isoform [3]. Recently it has been shown in B cell lymphomas that MYC directly
upregulates several genes encoding core snRNP factors, and PRMT5 promotes the assembly of snRNP
factors [155]. This study showed that downregulation of PRMT5 altered splicing, including exon
skipping and intron retention, and inhibited lymphoma development in mice. This opens up a new
avenue of therapeutic targeting by developing pharmacologic inhibitors of PRMT5, as described
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earlier. However, it is important to consider the fact that PRMT5 has diverse substrates apart from
splicing factors. This fact is reflected in recent studies showing that cancer cells can be sensitized
upon PRMT5 inhibition via other mechanisms, unrelated to RNA processing [156,157]. Further
investigation is necessary to define the effects of pharmacologic inhibition of PRMT5 and its safety
margin in MYC-dependent cancers. In an effort to seek the essential genes in MYC-overexpressing
mammary epithelial cells, several splicing factors were identified, which are required to tolerate
MYC hyperactivation. Among them, one important factor is BUD31, which is important for multiple
subcomplexes of the spliceosome [150]. Downregulation of BUD31 resulted in global intron retention.
Taken together these data suggest that the oncogenic activity of MYC is preferentially dependent on
spliceosomal proteins, however, this is coordinated via differential mechanisms and is lineage specific.
Therefore, the therapeutic efficacy of splicing modulation by targeting splicing factors and specificity
for MYC-driven cancers should be further investigated.
4.5. Targeting mRNA Decay
Another approach is targeting other enzymatic steps in the mRNA decay pathway. One notable
example is the N6-adenosine methyltransferase (METTL3) catalyzing N6-adenosine methylation of
RNA, which is reported to be essential for the survival of certain cancer types, compared to healthy
cells [125,158]. This observation has increased interests in developing chemical inhibitors of the
METTL3 in cancer therapy [125,158]. Another potential target is the decapping enzyme scavenger
DCPS. This enzyme catalyzes the final step of 3′ to 5′ mRNA decay. A recent study reported that DCPS
is required for the survival of AML cells, although it is not essential for normal hematopoietic cells [159].
Several inhibitors of DCPS have been reported. One example is RG3039, which has completed a phase
I clinical trial for spinal muscular atrophy (SMA) and appeared safe in patients [160]. This is therefore
promising to assess the efficacy and safety margin of DCPS inhibitor in cancer therapy.
4.6. Targeted Splicing Modulation
An alternative and direct strategy is targeted modulation of a tumor-specific splicing event.
One attractive approach to do this is by using antisense oligonucleotides (ASOs), which are short
single-stranded nucleic acid molecules carrying different chemical modifications compared to RNA or
DNA. ASOs can bind to splicing regulatory sequences or motifs in a targeted transcript, and switch
splicing to a favorable isoform (Figure 2E) [161,162]. The target sequences can be splice sites (5′ SS or 3′
SS), silencers (ISS or ESS), or enhancers (ISE or ESE), which are normally recognized by the core splicing
machinery or by RNA-binding splicing regulatory protein(s) (activator or suppressor). Therefore,
antisense compounds can be designed to activate or inhibit a splicing event in a transcript-specific
manner. Due to the design against unique complementary sequences in the transcriptome, this approach
is efficient and expected to raise minimal off-target effects. The biggest challenge is targeting key
splicing events, which are essential for oncogenic transformation or maintenance of tumors, which
requires extensive studies and careful validations. Despite these challenges, ASO therapies are already
in the clinic, and many therapeutic ASOs against several diseases, including cancer, are now in clinical
trials [162–164]. For example, the ASO drug Nusinersen (Spinraza) corrects aberrant splicing of SMN2
and is an effective approved treatment for spinal muscular atrophy [162,165]. Nusinersen binds to
an intronic region flanking exon 7 in SMN2 pre-mRNA, encoding survival motor neuron protein,
and represses the recognition of exon 7 by the spliceosome. This subsequently enhances the inclusion
of exon 7 in the mRNA, and encodes a functional full-length protein, which is normally lacking in
spinal muscular atrophy due to homozygous mutations or deletions of the SMN1 gene [162,165,166].
Another example is the ASO drug Eteplirsen for the treatment of Duchenne muscular dystrophy [164].
Eteplirsen binds to a site in exon 51 of the DMD pre-mRNA encoding dystrophin, and sterically blocks
the recognition of exon 51 by the spliceosome. This subsequently promotes skipping of exon 51 and
rectifies the disease-causing frameshift mutation [164]. The resulting mRNA generates a short but
functional protein.
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ASO drugs in cancer therapy are still in developmental stages, with promising results in several
preclinical studies. One noteworthy example is the PKM gene which involves a choice between mutually
exclusive exons 9 and 10. PKM1 isoform includes exon 9 and promotes oxidative phosphorylation.
In contrast, the PKM2 isoform includes exon 10 and promotes aerobic glycolysis (the Warburg effect)
and is crucial for tumor growth. The PKM2 isoform is frequently expressed in cancers. ASOs that
impaire the expression of PKM2 elicit apoptosis in glioblastoma cell lines [167]. Recently, the antisense
approach has been tested in the context of spliceosomal-mutant cancer. As noted earlier, SF3B1
is the most commonly mutated RNA splicing factor in cancer. Diverse SF3B1 mutations converge
on repression of a critical target BRD9 [62], which is a core component of the non-canonical BAF
chromatin-remodeling complex. Mutant SF3B1 recognizes an aberrant, deep intronic branchpoint
within BRD9, and thereby promotes the inclusion of a poison exon [62]. This subsequently elicits
degradation of BRD9 mRNA via NMD [62]. Depletion of BRD9 causes the loss of non-canonical BAF
complex and promotes melanomagenesis. BRD9 is a potent tumor suppressor in uveal melanoma.
In an attempt to correct mis-splicing of BRD9, specific ASOs were employed both in vitro and in vivo,
which showed satisfactory results in splicing modulation and suppressing tumor growth [62].
In addition to ASOs, targeted modulation of a tumor-specific splicing event can also be achieved
using small molecules. For example, several studies identified compounds that enhance SMN2 exon 7
splicing to promote the production of a full-length SMN protein [102,168,169], which is promising for
therapeutic utility for spinal muscular atrophy. Similarly, another study identified small molecules that
promote the inclusion of exon 20 in IKBKAP pre-mRNA, which has shown promising results in familial
dysautonomia [170]. These molecules were initially screened using reporters in a model cell. Although
potential mechanisms have been proposed, further work is required to evaluate target specificity and
safety margin, and generalized application to other splicing targets.
5. Perspective
Splicing alterations in human tumors are a growing area of interest in cancer research and are
prospective targets for personalized cancer therapies. The advent of RNA-seq in recent years has
provided extensive information to identify altered splicing targets in cancer. Analysis of aberrant
splicing has not only uncovered the underlying maladies in cancer, but also allowed us to gain insight
on the physiological regulation of splicing. Although these studies have provided important primary
insights, we lack adequate information necessary to develop molecular therapies. One important
impediment is to screen out critical “driver splicing targets” among hundreds of splicing changes,
which are just the outcome of mutations or abnormal expression of splicing factors and not directly
associated with the disease, also referred as “passenger splicing events”. In addition, it is difficult to
ascertain the contribution of individual splicing events in the context of cancer. Moreover, the extent of
splicing changes are often variable among clinical patients and model cell lines, making it difficult to
target a promising splicing event for therapeutic correction. Systematic evaluation of the functional
roles of tumor-specific RNA isoforms will be greatly instructive in developing targeted therapies.
As we start understanding the biological consequences of splicing factor alterations in human tumors,
we realize that many of these splicing changes are cell-type-specific. Further efforts are therefore
necessary to dissect the precise roles of splicing factors in normal tissue and the consequences of
their dysregulation in the context of cancer with adequate resolution at the proteome level. A better
understanding of the cell-type specificity and functions of cancer-associated splicing factors will be
critical to identify novel biomarkers and develop new therapeutic strategies.
A number of chemical compounds have been reported that modulate splicing; however, most of
these drugs interfere with early spliceosome assembly (such as compounds targeting SF3B1) or
phosphorylation of splicing factors (such as SR proteins). Further efforts are necessary to screen
compounds targeting later stages of spliceosome assembly, which may be crucial in developing effective
splicing modulating drugs. Recent advances on the structural understanding of the spliceosome will
strongly help elucidate the mechanistic effects of these compounds and may help discover novel means
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of splicing modulation. While identifying new therapeutic modalities targeting splicing, it is important
to consider the therapeutic index, safety margin, and toxicity effects of splicing modulation in patients.
Systematic studies should carefully evaluate the feasibility of globally modifying RNA splicing in
patients. It is plausible that the widespread alterations in splicing that result from targeting spliceosome
assembly using chemical compounds may generate novel protein isoform(s), which could be exploited
in immunologically targeting cancer cells. Therefore, systematic evaluation of the effects of these
compounds at the proteome level is critical to expand our understanding of tumor pathogenesis and to
identify more effective drug candidates. Cutting-edge technologies, such as splicing and proteomic
profiling within single cells and single-molecule RNA-seq could be applied to gain novel insights into
splicing dysregulation in cancer.
The identification of functionally important pathologic RNA isoforms opens up the possibility
of antisense therapies for splicing alterations in cancer. Although antisense approaches to modulate
splicing in several human genetic diseases are reaching the clinic, they are still in developmental
stages in cancer therapies. More studies need to scrutinize antisense approaches for targeted and
personalized cancer therapies. Another recently emerging area in cancer therapy is targeting
neoepitopes generated by tumor-specific alternative splicing, which can be exploited to induce
T cell responses in cancer patients. Systematic detection of immunogenic neoantigens is required for
the successful development of potent vaccines. Recent studies show promising results in melanoma
by expanding neoantigen-specific T cell populations [171,172]. Despite the major advances toward
targeted cancer therapies, one critical challenge is the development of resistance to such treatments.
To address this challenge, studies are required to define the underlying molecular mechanisms that
drive tumorigenesis and links to distinct cellular and extracellular pathways that contribute to cancer
phenotypes, which will be crucial for the development of more effective drugs [32,173–180].
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Abbreviations
AML Acute myeloid leukemia
ASO Antisense oligonucleotides
ATR Ataxia telangiectasia and Rad3-related protein
B-NHL B-cell non-Hodgkin lymphoma
BP Branch point
CLK CDC2-like kinase
CLL Chronic lymphocytic leukemia
CP Cleavage and polyadenylation
EJCs Exon junction complexes
ESEs Exonic splicing enhancers
ESSs Exonic splicing silencers
HCC Hepatocellular carcinoma
hnRNPs Heterogeneous nuclear ribonucleoproteins
ISEs Intronic splicing enhancers
ISSs Intronic splicing silencers
MB Medulloblastoma
MDS Myelodysplastic syndrome
METTL3 N6-adenosine methyltransferase
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NMD Nonsense-mediated mRNA decay
PC Pancreatic adenocarcinoma
PPT Polypyrimidine tract
PTCs Premature termination codons
PRMT5 Protein arginine N-methyltransferase 5
PKM Pyruvate kinase
RNPs Ribonucleoproteins
RRM RNA-recognition motif
SRPK SR protein kinase family
snRNPs Small nuclear ribonucleoproteins
SS Splice site
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